Skip to main content
. 2014 Aug 4;9(8):e103551. doi: 10.1371/journal.pone.0103551

Figure 2. PI3K signaling in colorectal cancers (CRCs).

Figure 2

The respective p-values are indicated. (A) Box plots of the Mann–Whitney t-test showing the difference in the expression of pPI3K, pPI3K/pHER1, pPI3K/pHER2, and pPI3K/pHER3 between the high pPI3K/pHER3 group and low pPI3K/pHER3 groups. The respective p-values are indicated. (B) Table listing the characteristics of primary CRCs in high PI3K (high pPI3K/pHER3) versus low PI3K (low pPI3K/pHER3) signaling cohorts. Characteristics include segregations based on tumor stage, status of chemotherapy treatment, and mutational status of KRAS and BRAF. Altogether, 67/115 samples are included in the high PI3K cohort and 48/115 samples are included in the low PI3K cohort. The numbers indicate the percentage of samples within each cohort based on each indicated characteristic. (C) DFS according to pPI3K/pHER3 ratios in KRAS WT and KRAS G12mut CRCs. (D) Kaplan–Meier survival curves of high PI3K (pPI3K/pHER3) and low PI3K cohorts comparing the DFS of KRAS WT, G13Dmut, and G12mut samples. (E) high PI3K (high pPI3K/pHER3) and low PI3K (low pPI3K/pHER3) groups in paired primary and metastatic CRC samples.